{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:32:54Z","timestamp":1787725974227,"version":"build-2784847793"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Injection of botulinum toxin for cosmetic purposes is a well\u2010established practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study was conducted to compare the safety and efficacy of Dyston<jats:sup>\u00ae<\/jats:sup> (investigational biosimilar abobotulinumtoxinA) with Dysport<jats:sup>\u00ae<\/jats:sup> (abobotulinumtoxinA, Ipsen) in the treatment of moderate\u2010to\u2010severe glabellar lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Out of 193\u00a0screened subjects, 126 volunteers with moderate\u2010to\u2010severe glabellar lines fulfilling eligibility criteria were randomized in a 1:1 ratio to receive either an intramuscular injection of 40\u201360 units of Dyston<jats:sup>\u00ae<\/jats:sup> or Dysport<jats:sup>\u00ae<\/jats:sup>. The primary objective was to test the non\u2010inferiority of Dyston<jats:sup>\u00ae<\/jats:sup> compared with Dysport<jats:sup>\u00ae<\/jats:sup> as measured by the percentage of volunteers who achieved no or mild glabellar lines at maximum frown assessed by the physicians based on the Glabellar Line Severity Score (GLSS) at Day 30. Secondary endpoints included the improvement in the glabellar lines at maximum frown and rest states at Days 14, 60, 90, and 120 as well as the side effects of the treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Response rates at maximum frown were 75.44% (43\/57) in the Dyston<jats:sup>\u00ae<\/jats:sup> group and 76.67% (46\/60) in the Dysport<jats:sup>\u00ae<\/jats:sup> group on Day 30 (<jats:italic>p<\/jats:italic> value: 0.88, 95% CI: \u221214.24 to 16.70, diff: 1.23) as per\u2010protocol set, and were 75.81% (47\/62) and 76.19 (48\/63) (<jats:italic>p<\/jats:italic> value: 0.96, 95% CI: \u221214.59 to 15.35, diff: 0.3) in the Dyston<jats:sup>\u00ae<\/jats:sup> and the Dysport<jats:sup>\u00ae<\/jats:sup> groups, respectively, based on modified intention to treat population. Adverse events were similar in both groups and mostly mild and well\u2010tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment of moderate\u2010to\u2010severe glabellar lines with Dyston<jats:sup>\u00ae<\/jats:sup> was effective, tolerable, and non\u2010inferior compared with Dysport<jats:sup>\u00ae<\/jats:sup>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.14939","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T14:21:17Z","timestamp":1648390877000},"page":"2398-2406","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate\u2010to\u2010severe glabellar lines: A non\u2010inferiority double blinded randomized controlled trial"],"prefix":"10.1111","volume":"21","author":[{"given":"Seyyedeh Maryam","family":"Afshani","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"},{"name":"Medical Department Arta Pharmed Company  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-429X","authenticated-orcid":false,"given":"Aniseh","family":"Samadi","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin diseases and Leprosy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Ayatollahi","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin diseases and Leprosy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour Nassiri","family":"Kashani","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin diseases and Leprosy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Ahmad Nasdrollahi","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin diseases and Leprosy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin diseases and Leprosy Tehran University of Medical Sciences  Tehran Iran"},{"name":"Clinical Trial Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rezagholi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"},{"name":"Medical Department Arta Pharmed Company  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Hedayatjoo","sequence":"additional","affiliation":[{"name":"Medical Department Arta Pharmed Company  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delara","family":"Hazegh Fetratjoo","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"},{"name":"Medical Department Arta Pharmed Company  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Ghobadi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmirHossein","family":"Anari","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"},{"name":"Medical Department Arta Pharmed Company  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Saeedifar","sequence":"additional","affiliation":[{"name":"Imen Vaccine Alborz Biotechnology Research Center  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Firooz","sequence":"additional","affiliation":[{"name":"Center for Research and Training in Skin diseases and Leprosy Tehran University of Medical Sciences  Tehran Iran"},{"name":"Clinical Trial Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2003.29112.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006527-200501000-00003"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.116.012658"},{"key":"e_1_2_11_5_1","first-page":"1","article-title":"Botulinum toxin type\u2010A in the treatment of glabellar lines","volume":"3","author":"Winter L","year":"2010","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2013.09.009"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1992.tb03295.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins4100913"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e31818dbfe3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.06.011"},{"key":"e_1_2_11_11_1","unstructured":"Surgeons ASoP.Plastic surgery statistics report 2019;2019."},{"issue":"3","key":"e_1_2_11_12_1","first-page":"14","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"81","author":"Association GAotWM","year":"2014","journal-title":"J Am Coll Dent"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjx010"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12408"},{"issue":"4","key":"e_1_2_11_15_1","first-page":"413","article-title":"A multicenter, randomized, double\u2010blind, placebo\u2010controlled, single\u2010dose, phase III, non\u2010inferiority study comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients","volume":"40","author":"Rzany BJ","year":"2020","journal-title":"Aesthetic Surg J"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000001544"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjw282"},{"key":"e_1_2_11_18_1","first-page":"101","article-title":"Treating glabellar lines with botulinum toxin type A\u2010hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction","volume":"5","author":"Boulle K","year":"2010","journal-title":"Clin Interv Aging"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.asj.2009.09.012"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2007.00325.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2011.12.001"},{"issue":"12","key":"e_1_2_11_22_1","first-page":"E1","article-title":"Management of ptosis","volume":"9","author":"King M","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_11_23_1","unstructured":"LTD IB.Dysport monogragh. October2018."}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.14939","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:31:03Z","timestamp":1692829863000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.14939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/jocd.14939"],"URL":"https:\/\/doi.org\/10.1111\/jocd.14939","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"2022-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}